Potential COVID-19 vaccine jointly developed by Duke-NUS and Arcturus begins human trials

United States News News

Potential COVID-19 vaccine jointly developed by Duke-NUS and Arcturus begins human trials
United States Latest News,United States Headlines
  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 66%

SINGAPORE: The first participants of an early-stage COVID-19 vaccine trial have been given the potential vaccine, said Arcturus Therapeutics ...

SINGAPORE: The first participants of an early-stage COVID-19 vaccine trial have been given the potential vaccine, said Arcturus Therapeutics Holdings on Tuesday .

The potential vaccine is jointly developed by Arcturus and Singapore's Duke-NUS Medical School. Results from the trial are expected in the fourth quarter of this year.The company is among several drugmakers racing to develop a safe and effective vaccine for the new coronavirus that has killed more than 735,000 people globally.

In April, Arcturus said preclinical data testing of its experimental vaccine, known as ARCT-021, showed the vaccine candidate could trigger an immune response to the virus.

ARCT-021, like Moderna's COVID-19 vaccine candidate, uses mRNA, or messenger RNA, to inoculate against the coronavirus.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ChannelNewsAsia /  🏆 6. in SG

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Sinovac launches late-stage trial for potential COVID-19 vaccine in IndonesiaSinovac launches late-stage trial for potential COVID-19 vaccine in IndonesiaJAKARTA: China's Sinovac Biotech launched on Tuesday (Aug 11) a late-stage human trial involving as many as 1,620 patients in Indonesia for a ...
Read more »

Sinovac launches late-stage trial for potential Covid-19 vaccine in IndonesiaSinovac launches late-stage trial for potential Covid-19 vaccine in IndonesiaJAKARTA/BEIJING (REUTERS) - China's Sinovac Biotech launched on Tuesday(Aug 11) a late-stage human trial involving as many as 1,620 patients in Indonesia for a Covid-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.. Read more at straitstimes.com.
Read more »

Johnson & Johnson eyes 1 billion doses of potential Covid-19 shot in 2021, weighs challenge trialsJohnson & Johnson eyes 1 billion doses of potential Covid-19 shot in 2021, weighs challenge trialsBRUSSELS (REUTERS) - Johnson & Johnson could produce 1 billion doses of its potential Covid-19 vaccine next year if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there are not enough patients for final trials, a company executive said.. Read more at straitstimes.com.
Read more »

J&J eyes 1 billion doses of potential COVID-19 shot in 2021, weighs challenge trialsJ&J eyes 1 billion doses of potential COVID-19 shot in 2021, weighs challenge trialsBRUSSELS: Johnson & Johnson could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider ...
Read more »

China's Sinopharm starts Phase III trial of COVID-19 vaccine in BahrainChina's Sinopharm starts Phase III trial of COVID-19 vaccine in BahrainChinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar ...
Read more »



Render Time: 2025-02-25 05:17:09